17-Apr-2026
No headlines found.
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Wed, 8-Apr 4:05 PM ET)
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Mon, 16-Mar 4:02 PM ET)
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 9-Mar 7:00 AM ET)
Globe Newswire (Mon, 23-Feb 5:10 PM ET)
Kyntra Bio to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 17-Feb 4:05 PM ET)
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
Kyntra Bio trades on the NASDAQ stock market under the symbol KYNB.
As of April 17, 2026, KYNB stock price climbed to $7.32 with 4,022 million shares trading.
KYNB has a beta of 1.66, meaning it tends to be more sensitive to market movements. KYNB has a correlation of 0.15 to the broad based SPY ETF.
KYNB has a market cap of $29.61 million. This is considered a Sub-Micro Cap stock.
Last quarter Kyntra Bio reported $1 million in Revenue and -$3.61 earnings per share. This fell short of revenue expectation by $-342,000 and exceeded earnings estimates by $.28.
The top ETF exchange traded funds that KYNB belongs to (by Net Assets): VTI, VXF.
KYNB support price is $6.89 and resistance is $7.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYNB shares will trade within this expected range on the day.